Repligen Corp. Stock
Price
Target price
€99.98
€99.98
-6.540%
-7.0
-6.540%
€172.32
18.07.25 / Tradegate
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Repligen Corp. Stock
Repligen Corp. took a tumble today and lost -€7.000 (-6.540%).
We see a rather positive sentiment for Repligen Corp. with 15 Buy predictions and 1 Sell predictions.
As a result the target price of 172 € shows a very positive potential of 72.03% compared to the current price of 99.98 € for Repligen Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Repligen Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Repligen Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -6.540% | -8.861% | -2.411% | -19.273% | -28.560% | -36.810% | -14.802% |
| Opko Health Inc. | 2.650% | 3.167% | 1.677% | -15.229% | -17.927% | -58.088% | -67.391% |
| Amicus Therapeutics Inc. | 13.860% | 8.491% | 15.462% | -40.104% | -37.158% | -45.928% | -56.767% |
| Indivior plc | 0.730% | 5.344% | 13.115% | 40.816% | 15.966% | -23.333% | 213.993% |
Comments
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $150.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
